摘要
Background:Promoting wound healing is crucial to restore the vital barrier function of injured skin.Growth factor products including epidermal growth factor(EGF),fibroblast growth factor(FGF)and granulocyte-macrophage colony stimulating factor(GM-CSF)have been used for decades although no systematic evaluation exists regarding their effectiveness and safety issues in treating acute skin wounds.This has resulted in a lack of guidelines and standards for proper application regimes.Therefore,this systematic review and meta-analysis was performed to critically evaluate the effectiveness and safety of these growth factors on skin acute wounds and provide guidelines for application regimes.Methods:We searched PubMed/Medline(1980-2020),Cochrane Library(1980-2020),Cochrane CENTRAL(from establishment to 2020),ClinicalTrials.gov(from establishment to 2020),Chinese Journal Full-text Database(CNKI,1994-2020),China Biology Medicine disc(CBM,1978-2019),Chinese Scientific Journal Database(VIP,1989-2020)andWanfang Database(WFDATA,1980-2019).Randomized controlled trials(RCTs),quasi-RCTs and controlled clinical trials treating patients with acute skin wounds from various causes and with those available growth factors were included.Results:A total of 7573 papers were identified through database searching;229 papers including 281 studies were kept after final screening.Administering growth factors significantly short-ened the healing time of acute skin wounds,including superficial burn injuries[mean differ-ence(MD)=−3.02;95%confidence interval(CI):−3.31∼−2.74;p<0.00001],deep burn injuries(MD=−5.63;95%CI:−7.10∼−4.17;p<0.00001),traumata and surgical wounds(MD=−4.50;95%CI:−5.55∼−3.44;p<0.00001).Growth factors increased the healing rate of acute skin wounds and decreased scar scores.The incidence of adverse reactions was lower in the growth factor treatment group than in the non-growth factor group.Conclusions:The studied growth factors not only are effective and safe for managing acute skin wounds,but also accelerate their healing with no severe adverse reactions.
